Back to Browse Journals » Journal of Pain Research » Volume 3

Milnacipran for the management of fibromyalgia syndrome

Authors Michelle J Ormseth, Anne E Eyler, Cara L Hammonds, et al

Published Date March 2010 Volume 2010:3 Pages 15—24

DOI http://dx.doi.org/10.2147/JPR.S7883

Published 1 March 2010

Michelle J Ormseth, Anne E Eyler, Cara L Hammonds, Chad S Boomershine

Division of Rheumatology and Immunology, Vanderbilt University, Nashville, TN, USA

Abstract: Fibromyalgia syndrome (FMS) is a widespread pain condition associated with fatigue, cognitive dysfunction, sleep disturbance, depression, anxiety, and stiffness. Milnacipran is one of three medications currently approved by the Food and Drug Administration in the United States for the management of adult FMS patients. This review is the second in a three-part series reviewing each of the approved FMS drugs and serves as a primer on the use of milnacipran in FMS treatment including information on pharmacology, pharmacokinetics, safety and tolerability. Milnacipran is a mixed serotonin and norepinephrine reuptake inhibitor thought to improve FMS symptoms by increasing neurotransmitter levels in descending central nervous system inhibitory pathways. Milnacipran has proven efficacy in managing global FMS symptoms and pain as well as improving symptoms of fatigue and cognitive dysfunction without affecting sleep. Due to its antidepressant activity, milnacipran can also be beneficial to FMS patients with coexisting depression. However, side effects can limit milnacipran tolerability in FMS patients due to its association with headache, nausea, tachycardia, hyper- and hypotension, and increased risk for bleeding and suicidality in at-risk patients. Tolerability can be maximized by starting at low dose and slowly up-titrating if needed. As with all medications used in FMS management, milnacipran works best when used as part of an individualized treatment regimen that includes resistance and aerobic exercise, patient education and behavioral therapies.
Keywords: fibromyalgia, milnacipran, treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Duloxetine in the management of diabetic peripheral neuropathic pain

Ormseth MJ, Scholz BA, Boomershine CS

Patient Preference and Adherence 2011, 5:343-356

Published Date: 19 July 2011

Pregabalin for the management of fibromyalgia syndrome

Chad S Boomershine

Journal of Pain Research 2010, 3:81-88

Published Date: 22 June 2010

Duloxetine for the management of fibromyalgia syndrome

Beth A Scholz, Cara L Hammonds, Chad S Boomershine

Journal of Pain Research 2009, 2:99-108

Published Date: 21 July 2009

Readers of this article also read:

Factors associated with inadequate diagnosis of COPD: On-Sint cohort analysis

Fernández-Villar A, López-Campos JL, Represas Represas C, Marín Barrera L, Leiro Fernández V, López Ramírez C, Casamor R

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:961-967

Published Date: 18 May 2015

Wearing-off in Parkinson’s disease: neuropsychological differences between on and off periods

Caillava-Santos F, Margis R, Rieder CR

Neuropsychiatric Disease and Treatment 2015, 11:1175-1180

Published Date: 13 May 2015

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]

Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C

Clinical Pharmacology: Advances and Applications 2014, 6:61-62

Published Date: 27 March 2014

Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo

Xiang DX, Zheng Y, Duan W, Li XJ, Yin JJ, Shigdar S, O'Connor ML, Marappan M, Zhao XJ, Miao YQ, Xiang B, Zheng CL

International Journal of Nanomedicine 2013, 8:4103-4114

Published Date: 30 October 2013

The Treatment Effectiveness Assessment (TEA)

Ling W, Farabee D, Liepa D, Wu LT

Substance Abuse and Rehabilitation 2013, 4:73-74

Published Date: 24 September 2013

Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm [Corrigendum]

Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L

International Journal of Nanomedicine 2013, 8:2129-2130

Published Date: 13 June 2013

Corrigendum

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Erratum

Marusza W, Mlynarczyk G, Olszanski R, Netsvyetayeva I, Obrowski M, Iannitti T, Palmieri B

International Journal of Nanomedicine 2012, 7:4119-4120

Published Date: 27 July 2012

Further data on the association between Helicobacter pylori infection and primary open-angle glaucoma

Zavos C, Kountouras J

Clinical Ophthalmology 2012, 6:243-245

Published Date: 10 February 2012